Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1957 1
1958 1
1960 2
1961 1
1964 1
1966 1
2000 2
2001 1
2002 2
2003 1
2004 3
2005 4
2006 2
2007 4
2009 2
2012 1
2013 1
2014 2
2015 1
2018 1
2019 2
2020 2
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Endometrial cancer: a review and current management strategies: part I.
SGO Clinical Practice Endometrial Cancer Working Group; Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F; Society of Gynecologic Oncology Clinical Practice Committee. SGO Clinical Practice Endometrial Cancer Working Group, et al. Among authors: villella j. Gynecol Oncol. 2014 Aug;134(2):385-92. doi: 10.1016/j.ygyno.2014.05.018. Epub 2014 Jun 4. Gynecol Oncol. 2014. PMID: 24905773 Review.
Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.
Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO. Zhu Q, et al. Among authors: villella j. Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16. Int J Cancer. 2020. PMID: 31265121 Free PMC article.
Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers.
Zhu Q, Wang J, Yu H, Hu Q, Bateman NW, Long M, Rosario S, Schultz E, Dalgard CL, Wilkerson MD, Sukumar G, Huang RY, Kaur J, Lele SB, Zsiros E, Villella J, Lugade A, Moysich K, Conrads TP, Maxwell GL, Odunsi K. Zhu Q, et al. Among authors: villella j. Cancers (Basel). 2022 May 10;14(10):2350. doi: 10.3390/cancers14102350. Cancers (Basel). 2022. PMID: 35625955 Free PMC article.
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.
Dorigo O, Oza AM, Pejovic T, Ghatage P, Ghamande S, Provencher D, MacDonald LD, Torrey H, Kaliaperumal V, Ebrahimizadeh W, Hirsch HA, Bramhecha Y, Villella J, Fiset S. Dorigo O, et al. Among authors: villella j. Clin Cancer Res. 2023 Aug 1;29(15):2808-2815. doi: 10.1158/1078-0432.CCR-22-2595. Clin Cancer Res. 2023. PMID: 37126016 Free PMC article. Clinical Trial.
43 results